HDAC9 and breast neoplasm: FTY720 also reduced HDAC activity in breast tumors (Figure 5d), concomitant with marked production of nuclear FTY720-P compared with FTY720 (Figure 5e) and increased mRNA levels of ERα and PR, without affecting expression of ErbB2 (Figure 5f).